Sanofi India reports Q3 growth, declares interim dividend

Sanofi India Limited reported strong financial performance for the quarter and nine months ended September 30, 2025. The company's revenue from operations for the quarter rose to ₹4,754 million from ₹4,063 million in the previous quarter, with total income reaching ₹4,803 million. Profit for the period from continuing operations was ₹760 million for the quarter and ₹2,650 million for the nine-month period.

The board of directors, at their meeting on October 29, 2025, approved the unaudited financial statements and declared an interim dividend of ₹75 per equity share (face value ₹10) for the year 2025. This dividend will be paid within 30 days of declaration, with Friday, November 7, 2025, set as the record date. The meeting also noted the company’s July 16, 2025, promotion and distribution agreement with Emcure Pharmaceuticals for its Oral Anti-diabetic (OAD) products.